---
title: "LanzaTech Announces Date for Second Quarter 2026 Earnings Release and Conference Call | LNZA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287773266.md"
description: "LanzaTech Announces Date for Second Quarter 2026 Earnings Release and Conference Call | LNZA Stock News"
datetime: "2026-05-27T04:40:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287773266.md)
  - [en](https://longbridge.com/en/news/287773266.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287773266.md)
generator: "portal-rs"
---

# LanzaTech Announces Date for Second Quarter 2026 Earnings Release and Conference Call | LNZA Stock News

LanzaTech Announces Date for Second Quarter 2026 Earnings Release and Conference Call | LNZA Stock News

### Related Stocks

- [LNZA.US](https://longbridge.com/en/quote/LNZA.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LNZAW.US](https://longbridge.com/en/quote/LNZAW.US.md)

## Related News & Research

- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [LNZA: Q2 2026 delivered stable revenue, major cost reductions, and expanded market access via certification](https://longbridge.com/en/news/295929848.md)
- [Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC](https://longbridge.com/en/news/298830378.md)
- [LanzaTech Reports Second Quarter 2026 Financial Results | LNZA Stock News](https://longbridge.com/en/news/295929751.md)
- [LanzaTech Global, Inc. (NASDAQ:LNZA) Sees Significant Growth in Short Interest](https://longbridge.com/en/news/292957931.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**